About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Tighter Federal Steps Aim to Deflate Crisis
Hospitals and their pharmacy departments are now at the epicenter of the prescription drug-abuse tsunami. The Obama administration is using regulatory agencies in an to attempt to crack down on physician-run "pill mills" and the pharmacies that support them.
The authors found that two-thirds of drugs approved by the FDA in recent years lacked adequate efficacy and safety information for use in older patients. With an expected doubling of the elderly population by 2040, it is time for pharmaceutical manufacturers to incorporate more robust prescribing information into their product labels of drugs used in this patient population.
Trevor Hinshaw; Joan Kapusnik-Uner, PharmD; Barbara Zarowitz, PharmD; and Karl Matuszewski, MS, PharmD
Part 1: The Clinical Significance of Pharmacogenetic Variants
As genotyping and genetic testing become more sophisticated, accessible, and cost-effective, these tools hold great promise for predicting and improving responses to medications.
C. Lee Ventola, MS
Controversies in Practice
A Closer Look at Media Messages Versus Research Findings
Although fish and fish oil supplements have been touted for their many benefits, especially in the treatment of cardiovascular disease, recent headlines have suggested that they might be linked to an increased risk of prostate cancer. P&T takes a closer look behind the mixed messages.
Mixups with local and topical epinephrine have led to fatalities.
Matthew Grissinger, RPh, FASCP
Drug Companies Push to Rein in 340B Discount Drugs
FDA approvals, drug indications, and updates
Afatinib (Gilotrif) for non–small-cell lung cancer; golimumab (Simponi Aria) for moderate-to-severe active rheumatoid arthritis; and levomilnacipran (Fetzima) extended release for major depressive disorder
Marvin M. Goldenberg, PhD, RPh, MS
A Selective Serotonin 5-HT2C Agonist in the Treatment of Obesity
Lorcaserin (Belviq) for the treatment of obesity
Ashley Gustafson, PharmD; Camille King, PharmD; and Jose A. Rey, PharmD, BCPP